Index - P/E - EPS (ttm) -2.64 Insider Own 0.88% Shs Outstand 492.85M Perf Week 1.12%
Market Cap 8.49B Forward P/E 16.08 EPS next Y 1.07 Insider Trans 0.88% Shs Float 489.82M Perf Month 26.68%
Income -1302.00M PEG - EPS next Q 0.24 Inst Own 97.99% Short Float 2.75% Perf Quarter 5.78%
Sales 4.37B P/S 1.95 EPS this Y 5.74% Inst Trans -3.01% Short Ratio 3.07 Perf Half Y 50.66%
Book/sh 12.26 P/B 1.40 EPS next Y 13.61% ROA -8.74% Short Interest 13.47M Perf Year 98.73%
Cash/sh 0.70 P/C 24.62 EPS next 5Y 2.33% ROE -19.24% 52W Range 7.88 - 17.43 Perf YTD 15.37%
Dividend Est. - P/FCF 31.00 EPS past 5Y - ROI -11.05% 52W High -1.38% Beta 1.45
Dividend TTM - Quick Ratio 1.96 Sales past 5Y 9.00% Gross Margin 42.75% 52W Low 118.15% ATR (14) 0.60
Dividend Ex-Date - Current Ratio 3.29 EPS Y/Y TTM -5619.91% Oper. Margin 5.45% RSI (14) 71.76 Volatility 2.24% 3.92%
Employees 9800 Debt/Eq 0.95 Sales Y/Y TTM -1.91% Profit Margin -29.83% Recom 2.07 Target Price 19.09
Option/Short Yes / Yes LT Debt/Eq 0.95 EPS Q/Q -69.14% Payout - Rel Volume 1.26 Prev Close 16.98
Sales Surprise 1.45% EPS Surprise 24.09% Sales Q/Q -4.14% Earnings May 08 BMO Avg Volume 4.39M Price 17.19
SMA20 17.82% SMA50 13.87% SMA200 29.16% Trades
Volume 5,540,367 Change 1.24%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Upgrade Stifel
Hold → Buy
$13 → $20
Dec-19-23 Initiated Jefferies
Buy
$17
Dec-15-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$16
Dec-07-23 Initiated Exane BNP Paribas
Outperform
$18
Apr-20-23 Upgrade Barclays
Equal Weight → Overweight
$14
Aug-18-22 Downgrade Morgan Stanley
Overweight → Equal-Weight
$37 → $22
Aug-16-22 Downgrade JP Morgan
Overweight → Neutral
$28 → $24
Jul-21-22 Downgrade Goldman
Buy → Sell
$32 → $19
Jul-12-22 Initiated Piper Sandler
Neutral
$22
Nov-18-21 Initiated Morgan Stanley
Overweight
$40
Oct-28-21 Downgrade Stifel
Buy → Hold
$37 → $34
Aug-05-21 Resumed Credit Suisse
Outperform
$38
Jun-15-21 Upgrade Cleveland Research
Underperform → Neutral
May-11-21 Upgrade Gabelli & Co
Hold → Buy
May-11-21 Upgrade Barclays
Underweight → Equal Weight
$25 → $29
Apr-15-21 Initiated Stifel
Buy
$37
Mar-22-21 Downgrade Gabelli & Co
Buy → Hold
Feb-26-21 Upgrade Credit Suisse
Neutral → Outperform
$33 → $38
Dec-09-20 Downgrade Argus
Buy → Hold
Nov-09-20 Downgrade Barclays
Overweight → Underweight
$35 → $25
Show Previous Ratings
May-13-24 09:17AM
May-09-24 08:54PM
11:33AM
10:26AM
09:44AM
07:43AM
Loading…
07:43AM
(The Wall Street Journal)
03:05AM
May-08-24 04:04PM
(Investor's Business Daily) +24.93%
02:00PM
12:32PM
09:30AM
09:18AM
07:52AM
07:25AM
06:28AM
09:15AM
Loading…
May-06-24 09:15AM
Apr-25-24 11:27AM
Apr-23-24 08:30AM
Apr-21-24 10:39AM
Apr-17-24 08:00AM
Apr-01-24 07:00AM
06:39AM
06:30AM
Mar-31-24 11:37PM
Mar-13-24 02:21PM
Mar-12-24 07:00PM
Mar-05-24 10:15AM
Mar-04-24 08:33AM
Feb-29-24 03:30PM
01:08PM
08:00AM
Loading…
08:00AM
07:03AM
Feb-28-24 10:58AM
Feb-26-24 11:41PM
(Thomson Reuters StreetEvents)
02:15PM
09:30AM
06:52AM
06:27AM
Feb-22-24 08:00AM
Feb-21-24 09:15AM
Feb-19-24 10:00AM
Feb-15-24 07:00AM
Feb-13-24 01:09PM
Feb-09-24 10:15AM
Feb-08-24 02:46PM
08:00AM
Feb-07-24 01:25PM
Feb-05-24 07:01AM
(The Wall Street Journal) +7.94%
06:48AM
06:36AM
06:33AM
06:33AM
Jan-18-24 08:22PM
Jan-17-24 08:30AM
Jan-08-24 07:35AM
Jan-02-24 08:33AM
Jan-01-24 09:15AM
Dec-19-23 08:00AM
Dec-14-23 05:08PM
Dec-08-23 09:00AM
Dec-07-23 04:37PM
Nov-27-23 08:00AM
Nov-10-23 05:20PM
Nov-09-23 03:49AM
Nov-08-23 04:03PM
12:21AM
(Thomson Reuters StreetEvents)
Nov-07-23 01:45PM
09:30AM
07:31AM
07:03AM
06:33AM
Nov-02-23 11:33AM
08:00AM
07:16AM
Nov-01-23 09:00AM
Oct-30-23 04:32PM
Oct-17-23 04:57PM
08:00AM
Oct-09-23 09:55AM
Oct-06-23 12:05PM
08:36AM
Oct-05-23 11:22AM
Oct-04-23 06:30AM
Sep-19-23 06:20AM
04:23AM
Sep-12-23 06:40AM
Sep-07-23 04:15PM
Sep-05-23 05:00PM
Aug-09-23 10:36AM
07:56AM
Aug-08-23 12:16AM
(Thomson Reuters StreetEvents)
Aug-07-23 02:30PM
12:34PM
09:30AM
07:50AM
06:33AM
Aug-02-23 07:10AM
06:55AM
Market Digest: CCI, CCI, ASH, ITW, MAR, MDC, SHEL, SANM, LEA, ANET, ELAN
(Argus Research)
Jul-20-23 08:00AM
Jul-18-23 08:00AM
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DOYLE WILLIAM F Director Mar 08 '24 Buy 16.30 15,000 244,500 61,330 Mar 12 04:32 PM Harrington Michael J Director Mar 08 '24 Buy 16.29 3,100 50,494 77,594 Mar 12 04:30 PM HOOVER R DAVID Director Mar 06 '24 Buy 16.14 20,000 322,808 185,000 Mar 08 05:09 PM
Index - P/E - EPS (ttm) -1.81 Insider Own 9.96% Shs Outstand 107.08M Perf Week 33.52%
Market Cap 2.37B Forward P/E - EPS next Y -1.76 Insider Trans -0.10% Shs Float 96.89M Perf Month 82.49%
Income -192.74M PEG - EPS next Q -0.41 Inst Own 83.64% Short Float 5.82% Perf Quarter 36.25%
Sales 525.66M P/S 4.50 EPS this Y 15.93% Inst Trans 2.95% Short Ratio 4.15 Perf Half Y 73.42%
Book/sh 3.34 P/B 6.58 EPS next Y -7.26% ROA -16.79% Short Interest 5.64M Perf Year -71.97%
Cash/sh 8.12 P/C 2.71 EPS next 5Y - ROE -48.70% 52W Range 10.87 - 83.47 Perf YTD 47.29%
Dividend Est. - P/FCF - EPS past 5Y -22.97% ROI -20.19% 52W High -73.66% Beta 0.80
Dividend TTM - Quick Ratio 5.99 Sales past 5Y 17.16% Gross Margin 74.97% 52W Low 102.30% ATR (14) 1.08
Dividend Ex-Date - Current Ratio 6.26 EPS Y/Y TTM -34.69% Oper. Margin -39.07% RSI (14) 84.57 Volatility 8.54% 6.43%
Employees 1453 Debt/Eq 1.66 Sales Y/Y TTM 0.61% Profit Margin -36.67% Recom 2.14 Target Price 25.50
Option/Short Yes / Yes LT Debt/Eq 1.66 EPS Q/Q 28.06% Payout - Rel Volume 0.85 Prev Close 22.17
Sales Surprise 5.37% EPS Surprise 14.29% Sales Q/Q 13.36% Earnings May 02 BMO Avg Volume 1.36M Price 21.99
SMA20 46.04% SMA50 51.17% SMA200 35.93% Trades
Volume 1,150,050 Change -0.81%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed JP Morgan
Neutral
$15
Aug-28-23 Downgrade H.C. Wainwright
Buy → Neutral
$85 → $25
Aug-08-23 Upgrade Piper Sandler
Neutral → Overweight
$45
Aug-04-23 Initiated SVB Securities
Outperform
$51
Jul-31-23 Upgrade Evercore ISI
Underperform → In-line
$33
Jun-07-23 Upgrade Wedbush
Underperform → Neutral
$53 → $46
May-16-23 Upgrade Wells Fargo
Equal Weight → Overweight
$70 → $104
Mar-17-23 Downgrade JP Morgan
Neutral → Underweight
$99 → $50
Jan-06-23 Downgrade Wells Fargo
Overweight → Equal Weight
$89 → $107
Jan-05-23 Reiterated H.C. Wainwright
Buy
$100 → $140
Nov-29-22 Upgrade Wells Fargo
Equal Weight → Overweight
$74 → $89
Oct-24-22 Downgrade Piper Sandler
Overweight → Neutral
$90 → $70
Jul-05-22 Downgrade Evercore ISI
In-line → Underperform
May-16-22 Initiated H.C. Wainwright
Buy
$115
Feb-08-22 Initiated Loop Capital
Buy
$200
Feb-02-22 Upgrade Oppenheimer
Perform → Outperform
$98
Jan-20-22 Upgrade Truist
Hold → Buy
$125
Jan-03-22 Upgrade Evercore ISI
Underperform → In-line
$82
Jul-01-21 Downgrade Mizuho
Buy → Neutral
Apr-14-21 Downgrade Wedbush
Neutral → Underperform
$159 → $154
Show Previous Ratings
May-14-24 07:08AM
May-10-24 05:14PM
May-03-24 12:08PM
01:00AM
May-02-24 01:19PM
11:56AM
Loading…
11:56AM
08:45AM
08:25AM
07:28AM
(Associated Press Finance)
07:01AM
07:00AM
Apr-25-24 10:01AM
Apr-24-24 10:45AM
Apr-05-24 07:00AM
Apr-04-24 11:33AM
12:00PM
Loading…
Apr-01-24 12:00PM
07:00AM
Mar-30-24 06:34AM
Mar-28-24 11:50AM
05:01AM
Mar-27-24 04:08PM
(Investor's Business Daily) +12.01%
09:29AM
09:16AM
(Investor's Business Daily)
07:14AM
07:12AM
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
12:15PM
Loading…
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
(Associated Press Finance)
07:00AM
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
(Associated Press Finance)
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
(Investor's Business Daily)
02:19PM
(Investor's Business Daily)
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 04 '24 Sale 16.01 1,217 19,484 251,235 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 04 '24 Sale 16.01 840 13,448 160,098 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Mar 01 '24 Sale 16.03 2,107 33,769 252,452 Mar 05 04:09 PM Leonard Frank X EVP, Pres., Novocure Oncology Mar 01 '24 Sale 16.03 1,679 26,909 160,938 Mar 05 04:08 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Feb 28 '24 Sale 16.14 2,303 37,177 254,559 Feb 29 04:28 PM Leonard Frank X EVP, Pres., Novocure Oncology Feb 28 '24 Sale 16.14 2,078 33,545 162,617 Feb 29 04:38 PM Shah Pritesh Chief Growth Officer Nov 07 '23 Sale 12.65 382 4,832 124,511 Nov 08 04:22 PM Cordova Ashley Chief Financial Officer Nov 02 '23 Option Exercise 11.46 175 2,006 117,618 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Oct 31 '23 Option Exercise 9.58 17,793 170,447 117,443 Nov 02 04:20 PM Cordova Ashley Chief Financial Officer Sep 01 '23 Sale 21.82 883 19,265 99,650 Sep 05 04:24 PM GROENHUYSEN WILHELMUS CM Chief Operating Officer Sep 01 '23 Sale 21.82 294 6,414 209,825 Sep 05 04:24 PM Shah Pritesh Chief Growth Officer Sep 01 '23 Sale 21.82 273 5,956 124,893 Sep 05 04:23 PM Cordova Ashley Chief Financial Officer Aug 02 '23 Sale 30.25 1,144 34,607 100,533 Aug 04 04:02 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
